NCIC CLINICAL TRIALS GROUP

GENITO URINARY

AGENDA
DISEASE SITE COMMITTEE MEETING
Delta Chelsea Hotel, Toronto, ON
Saturday, May 3, 2008
9:00 a.m. – 3:30 p.m.
Room: Rossetti

Chair: Fred Saad

9:00 WELCOME, APPROVAL OF FALL MEETING MINUTES
Chairman’s Report: NCI US Grant, Executive Retreat

9:10 NCIC CTG PHASE III TRIALS: OPEN
BL 8 / EORTC 30994
BL.11
PR.8/SWOG 9346
PR.11
PR.12
PR.13 (RADICALS) / MRC PR.10
PRP.1B – open to accrued patients

9:10 NCIC CTG PHASE III TRIALS: CLOSED
PR.7/PR.7 Bone Sub Study
PR.3
PRP.1

10:10 NCIC CTG TRIALS APPROVED/PENDING ACTIVATION
None

10:30 BREAK

10:50 CTSU TRIALS ENDORSED/ACTIVATED BY NCIC CTG
PRC.2/CALGB 90202 HT with or without zoledronic acid in hormone naïve met CaP
PRC.3/CALGB 90203 Neoadjuvant Taxotere plus AS prior to RP v.s. RP only
REC.2/ECOG 2805 Sunitinib/placebo or Sorafenib / Placebo in resected RCC

10:50 CTSU TRIALS PENDING ENDORSEMENT/ACTIVATION
None

continued...
11:20 **NCIC CTG IND TRIALS**
IND.165 Randomized Phase II (OGX-011 +/- docetaxel HRPC) (closed) K. Chi

11:25 **OPEN CUOG TRIALS**
CUOG-R-05 Role of Delayed Treatment for Early Stage RCCa M. Jewett
CUOG-P-05 RCT Risedronate vs Placebo for the Prevention of Androgen Deprivation Bone Loss in Non-Metastatic Prostate Cancer F. Saad
CUOG/CRUC CHICS Trial L. Klotz
CUOG P-06a Phase III trial of docetaxel +/- high dose Calcitriol K. Chi
CUOG P-06b Phase II Study of Patupilone (Epo906a) As A 2nd Line Therapy in HRPC K. Chi
CUOG P-06c Phase II Study of OGX-011 + mitoxantrone vs. OGX-011 + docetaxel as A 2nd Line Chemotherapy in HRPC F. Saad / E. Winquist
Sutent as salvage therapy in NSGCT C. Kollmannsberger
IAS plus dutasteride in PSA failures L. Klotz / S. Larry Goldenberg
ELAAT – early vs Late Androgen Ablation Therapy A. Loblaw

**PENDING CUOG TRIALS**
None

12:15 **LUNCH**

1:20 **CLOSED CUOG TRIALS**
Taxotere as Second Line in HRPC F. Saad
Iressa for Rising PSA post RP L. Klotz
CUOG B-05 BMS/CUOG second line bladder trial with vinflunine E. Winquist

1:40 **TRIALS UNDER DEVELOPMENT: CUOG**
Phase II Study of SU011248 for maintenance therapy in HRPC after 1st line Chemotherapy B. Eigl
Second-line bladder study (single arm Abraxane) Y. Ko
Randomized, placebo-controlled Phase II Study of SU011248 plus Best Supportive Care (BSC) versus Placebo plus BSC in patients with advanced urothelial carcinoma who have failed cisplatin containing chemotherapy T. Cheng
Temsirolimus second line RCC trial in Sutent Failure F. Saad / L. Wood

2:30 **NEW TRIAL PROPOSALS**
None for NCIC CTG
VEG TRAP (R1R2) proposal for CUOG

3:00 **OPEN DISCUSSION - NEW BUSINESS, STRATEGIC PLANNING**
Identifying liaisons between other working groups within the NCIC CTG (i.e. correlative sciences/tumour banking working group, psychosocial research working group, RTQA, etc)

3:30 **GU Executive (Closed)**